U.S. flag

An official website of the United States government

  • previous

NM_004628.5(XPC):c.2815C>A (p.Gln939Lys) AND cisplatin response - Toxicity/ADR

Germline classification:
drug response (1 submission)
Last evaluated:
May 3, 2017
Review status:
3 stars out of maximum of 4 stars
reviewed by expert panel
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000211268.1

Allele description

NM_004628.5(XPC):c.2815C>A (p.Gln939Lys)

Genes:
TMEM43:transmembrane protein 43 [Gene - OMIM - HGNC]
XPC:XPC complex subunit, DNA damage recognition and repair factor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
3p25.1
Genomic location:
Preferred name:
NM_004628.5(XPC):c.2815C>A (p.Gln939Lys)
HGVS:
  • NC_000003.12:g.14145949G>T
  • NG_011763.1:g.37724C>A
  • NM_001354726.1:c.2236C>A
  • NM_001354727.2:c.2809C>A
  • NM_001354729.1:c.2797C>A
  • NM_001354730.1:c.2569C>A
  • NM_004628.4:c.2815C>A
  • NM_004628.5:c.2815C>AMANE SELECT
  • NP_001341655.1:p.Gln746Lys
  • NP_001341656.1:p.Gln937Lys
  • NP_001341658.1:p.Gln933Lys
  • NP_001341659.1:p.Gln857Lys
  • NP_004619.3:p.Gln939Lys
  • NP_004619.3:p.Gln939Lys
  • LRG_472t1:c.2815C>A
  • LRG_472:g.37724C>A
  • LRG_472p1:p.Gln939Lys
  • NC_000003.11:g.14187449G>T
  • NR_148950.2:n.2687C>A
  • NR_148951.2:n.2563C>A
  • Q01831:p.Gln939Lys
Protein change:
Q746K
Links:
PharmGKB: 655386612; PharmGKB: 655386612PA449014; PharmGKB Clinical Annotation: 655386612; UniProtKB: Q01831#VAR_005848; dbSNP: rs2228001
NCBI 1000 Genomes Browser:
rs2228001
Molecular consequence:
  • NM_001354726.1:c.2236C>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354727.2:c.2809C>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354729.1:c.2797C>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354730.1:c.2569C>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_004628.4:c.2815C>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_004628.5:c.2815C>A - missense variant - [Sequence Ontology: SO:0001583]
  • NR_148950.2:n.2687C>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_148951.2:n.2563C>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
cisplatin response - Toxicity/ADR
Identifiers:
MedGen: CN236502

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000268257PharmGKB
reviewed by expert panel

(Pharmacogenomics knowledge for personalized medicine)
drug response
(May 3, 2017)
Condition: cisplatin response - Toxicity/ADR
Drug reported used for: Neoplasms
germlinecuration

PubMed (4)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedcuration

Citations

PubMed

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.

Caronia D, Patiño-García A, Milne RL, Zalacain-Díez M, Pita G, Alonso MR, Moreno LT, Sierrasesumaga-Ariznabarreta L, Benítez J, González-Neira A.

Pharmacogenomics J. 2009 Oct;9(5):347-53. doi: 10.1038/tpj.2009.19. Epub 2009 May 12.

PubMed [citation]
PMID:
19434073

Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer.

Sakano S, Hinoda Y, Sasaki M, Wada T, Matsumoto H, Eguchi S, Shinohara A, Kawai Y, Hara T, Nagao K, Hara T, Naito K, Matsuyama H.

Pharmacogenomics. 2010 Oct;11(10):1377-87. doi: 10.2217/pgs.10.106.

PubMed [citation]
PMID:
21047201
See all PubMed Citations (4)

Details of each submission

From PharmGKB, SCV000268257.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (4)

Description

PharmGKB Level of Evidence 1B: Annotation for a variant-drug combination where the preponderance of evidence shows an association. The association must be replicated in more than one cohort with significant p-values, and preferably will have a strong effect size.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jul 15, 2021